Atyr PHARMA (ATYR) Competitors

Atyr PHARMA (NASDAQ:ATYR) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Which has more risk and volatility, ATYR or IMTX?

Atyr PHARMA has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Immatics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Does the media refer more to ATYR or IMTX?

In the previous week, Atyr PHARMA and Atyr PHARMA both had 4 articles in the media. Atyr PHARMA's average media sentiment score of 0.73 beat Immatics' score of 0.73 indicating that Atyr PHARMA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atyr PHARMA	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ATYR or IMTX?

Atyr PHARMA presently has a consensus target price of $19.25, indicating a potential upside of 562.65%. Immatics has a consensus target price of $17.50, indicating a potential upside of 114.20%. Given Atyr PHARMA's higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atyr PHARMA	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immatics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in ATYR or IMTX?

Immatics received 21 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 73.68% of users gave Immatics an outperform vote.

Company	Underperform	Outperform
Atyr PHARMA	Outperform Votes 7 100.00%	Underperform Votes No Votes
Immatics	Outperform Votes 28 73.68%	Underperform Votes 10 26.32%

Do institutionals and insiders hold more shares of ATYR or IMTX?

61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by company insiders. Comparatively, 3.3% of Immatics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has higher earnings and valuation, ATYR or IMTX?

Atyr PHARMA has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Atyr PHARMA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atyr PHARMA	$588K	414.71	-$50.39M	-$0.94	-3.09
Immatics	$58.44M	16.69	-$104.98M	-$0.89	-9.18

Is ATYR or IMTX more profitable?

Atyr PHARMA has a net margin of 0.00% compared to Immatics' net margin of -103.99%. Immatics' return on equity of -23.34% beat Atyr PHARMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atyr PHARMA	N/A	-79.44%	-59.16%
Immatics	-103.99%	-23.34%	-13.22%

Summary

Atyr PHARMA beats Immatics on 10 of the 16 factors compared between the two stocks.